Researchers found that a single dose of a new treatment called VERVE-102 significantly lowered harmful cholesterol levels in people at high risk for heart disease. In a recent trial, participants experienced reductions in a protein called PCSK9 by up to 88% and a corresponding drop in low-density lipoprotein cholesterol (LDL-C) by as much as 62%. These effects were not only substantial but also lasted for up to 18 months, suggesting that VERVE-102 could offer a long-term solution for managing cholesterol with just one treatment.

This discovery is particularly important for individuals struggling with high cholesterol, especially those with conditions like heterozygous familial hypercholesterolemia (HeFH) or premature coronary artery disease (CAD). If proven effective in larger studies, VERVE-102 could provide a powerful option for lowering cholesterol levels, which is crucial for reducing the risk of heart attacks and other cardiovascular issues. The trial included 35 participants who had not achieved their cholesterol goals with existing medications, highlighting the potential of this treatment for people who need additional help.

Currently, VERVE-102 is in the early stages of clinical testing, specifically a Phase 1b trial. While the initial results are promising, they should be viewed with caution as more extensive research is needed to confirm its safety and effectiveness in larger populations. Lilly, the company behind VERVE-102, plans to advance to Phase 2 trials soon, which will further assess the treatment’s long-term impact and safety.

For now, if you’re concerned about cholesterol levels, it’s best to maintain a heart-healthy lifestyle, including a balanced diet, regular exercise, and routine check-ups with your healthcare provider. Keep an eye on developments regarding VERVE-102, as it may offer new hope in the future.

Source: investor.lilly.com